Posted by Michael Wonder on 21 Oct 2019
Farxiga approved in the US to reduce the risk of hospitalisation for heart failure in patients with type-2 diabetes
21 October 2019 - AstraZeneca today announced that the US FDA has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure in adults with type-2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.
The approval is based on results from the landmark DECLARE-TIMI 58 CV outcomes trial (CVOT), the largest sodium-glucose cotransporter 2 (SGLT2) inhibitor CVOT conducted to date to evaluate T2D patients with multiple CV risk factors or established CV disease.
